Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Itf2357

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
P 2 (1)

Trial Status

Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00887939Completed

Pathogenesis of Physical Induced Urticarial Syndromes

NCT00442182Phase 2UnknownPrimary

The Efficacy and Safety of ITF2357 in AIS

Showing all 2 trials

Research Network

Common Treatments

  • Itf23571

Active Sponsors

  • Radboud University Medical Center1
  • National Institute Of Allergy And Infectious Diseases Niaid1

Related Conditions

  • Hids1
  • Physical Urticaria1
  • Familial Cold Autoinflammatory Syndrome1
  • Traps1
  • Hypersensitivity Immediate1

Activity Timeline